Clinical trials
Small Cell Lung Cancer clinical trials
Below are recruiting small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 1,490 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07434947Recruiting
Rehabilitation benefits for advanced lung cancer after treatment
This trial tests whether a rehabilitation program can improve daily function and quality of life for people with advanced non-small cell lung cancer whose disease has been stable for at least 6 months. It aims to find the best way to measure the benefits of physical activity and support, so patients can feel better in their everyday lives.
AnnecyAges 18 years+ - NCT07428044RecruitingPhase 2
Trastuzumab Deruxtecan for HER2-mutant lung cancer before surgery
This trial tests a targeted drug, trastuzumab deruxtecan, for people with non-small cell lung cancer that has a specific HER2 gene change. The treatment is given before surgery to shrink the tumor and make it easier to remove.
Ann Arbor, MichiganAges 18 years+ - NCT07425795RecruitingPhase 2
Tislelizumab with chemo and radiation for first-line extensive SCLC
This trial tests a combination of an immunotherapy drug (tislelizumab), chemotherapy, and then radiation to the chest for people with extensive-stage small cell lung cancer who haven't had prior treatment. The goal is to see if this approach helps control the cancer longer.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT07434518Recruiting
Study of adebrelimab for advanced small cell lung cancer
This study looks at how well adebrelimab works and how safe it is in real-world settings for people with advanced small cell lung cancer that has spread. It may help doctors understand if this treatment is a good option for patients like you.
ShanghaiAges 18–100 - NCT07416474RecruitingPhase 3
Comparing two drug combos for first-line lung cancer
This trial tests a new drug (RC148) plus chemotherapy against another drug (Tislelizumab) plus chemotherapy for people with a type of lung cancer called squamous non-small cell lung cancer that has spread or can't be removed. It's for those who haven't had treatment for advanced disease yet.
Hefei, AnhuiAges 18–75 - NCT07424547RecruitingPhase 1
Study of SYS6043 for advanced or metastatic solid tumors
This trial tests a new study drug (SYS6043) for people with advanced or metastatic solid tumors that have not responded to or are not candidates for standard therapies. The drug targets a protein called B7-H3 on cancer cells to help stop tumor growth.
Plantation, FloridaAges 18 years+ - NCT07416994RecruitingPhase 3
Study of YL202 vs. docetaxel for advanced EGFR-mutant lung cancer
This trial tests a new drug, YL202, against a standard chemotherapy (docetaxel) for people with a specific type of advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if YL202 works better for those whose cancer has progressed after prior treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07423585RecruitingPhase 2
Tarlatamab for extensive stage small-cell lung cancer
This trial tests an experimental drug called tarlatamab for people newly diagnosed with extensive-stage small-cell lung cancer (SCLC). The goal is to see if tarlatamab can help shrink or control the cancer.
Columbus, OhioAges 18 years+ - NCT05257967Recruiting
Testing spinal fluid in EGFR-mutant lung cancer with brain covering spread
This trial looks at spinal fluid (also called CSF) in adults with EGFR-mutant lung cancer that has spread to the lining around the brain/spinal cord. The goal is to better understand the disease and what the spinal fluid tests may show to guide care.
Vancouver, British ColumbiaAges 18 years+ - NCT05745350RecruitingPhase 2
First treatment for extensive-stage small cell lung cancer
This trial studies how well pembrolizumab, plinabulin, and etoposide plus platinum work as first treatment for extensive-stage small cell lung cancer. It may help some people by boosting the immune response while also attacking cancer with standard chemotherapy.
Wuhan, HubeiAges 18 years+ - NCT06613009RecruitingPhase 1
New Drug IBI3009 for Advanced Small Cell Lung Cancer
This trial tests a new drug called IBI3009 for people with advanced small cell lung cancer that cannot be removed by surgery. It aims to see how safe the drug is and how well it works against the cancer.
Westmead, New South WalesAges 18–75 - NCT07407933RecruitingPhase 1/Phase 2
YL201 with other cancer drugs for advanced solid tumors
This trial tests a new drug, YL201, combined with other cancer treatments for people with a certain type of advanced lung cancer (extensive-stage small cell lung cancer). It may help shrink tumors or slow their growth.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07413757Recruiting
Study on factors in choosing lung cancer treatment
This study looks at what doctors and patients consider when deciding on a first-line treatment for advanced lung cancer. It aims to understand how choices are made for people taking a type of targeted therapy.
ChengduAges 18 years+ - NCT07412041Recruiting
Exercise program for stage II-III lung cancer before surgery
This study tests a personalized exercise program for people with stage II or III non-small cell lung cancer who are about to start cancer treatment before surgery. The goal is to see if exercise can help prepare your body for treatment and recovery.
Boston, MassachusettsAges 18 years+ - NCT07410975RecruitingPhase 2
Immunotherapy and chemo before surgery for lung cancer
This trial tests combining two immunotherapy drugs (anti-CTLA-4 antibody and sintilimab) with chemotherapy before surgery for stage II-III non-small cell lung cancer. The goal is to see if this approach helps shrink tumors and improve outcomes.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07415005RecruitingPhase 2
Lorlatinib and local therapy for ALK-positive lung cancer
This study combines a daily targeted pill (lorlatinib) with a short course of radiation or surgery to treat ALK-positive lung cancer. The goal is to see if this two-step approach delays the cancer from growing.
Houston, TexasAges 18 years+ - NCT07410494RecruitingPhase 1/Phase 2
Personalized donor cell therapy for advanced solid tumors
This trial tests a personalized cell therapy (CAR-NK) using donor immune cells that are engineered to find and attack one or two markers on advanced solid tumors. It may be an option for people whose tumors have these specific markers and have exhausted other treatments.
Beijing, Beijing MunicipalityAges 8–85 - NCT07408635RecruitingPhase 2
New Immunotherapy Plus Chemotherapy Before Lung Cancer Surgery
This trial tests a new combination of an immunotherapy drug (IBI363) plus chemotherapy before surgery in people with Stage III lung cancer that can't be removed at first. The goal is to shrink the tumor so it can be surgically removed.
ShanghaiAges 18 years+ - NCT07413042RecruitingPhase 1
Radiation drug combined with immunotherapy for extensive-stage small cell lung cancer
This trial tests a combination of a radioactive drug ([225Ac]Ac-DOTATATE) and an immunotherapy drug (Tislelizumab) as maintenance treatment for people with extensive-stage small cell lung cancer (ES-SCLC) whose tumors have a specific protein (SSTR). If you have completed first-line treatment and your cancer shows SSTR on a PET scan, this study may be an option.
Beijing, Beijing MunicipalityAges 18–80 - NCT07412262RecruitingPhase 2
Study of chidamide and ivonescimab for advanced lung cancer after immunotherapy resistance
This trial tests a combination of two drugs (chidamide and ivonescimab) for people with advanced non-small cell lung cancer that stopped responding to initial immunotherapy and has a specific protein marker (YAP) at high levels. It aims to see if this new combination can help when standard immunotherapy no longer works.
Guangzhou, GuangdongAges 18 years+ - NCT05669430RecruitingPhase 1/Phase 2
Testing an anti-cancer drug alone and with pembrolizumab
This early-phase study tests GV20-0251 (an anti-cancer treatment) by itself and combined with pembrolizumab, to see how well it works and how safe it is. It is for adults with advanced solid tumors that have grown despite standard treatments, or where standard treatments aren’t an option.
Los Angeles, CaliforniaAges 18 years+ - NCT07401498Enrolling by invitation
Studying side effects of lymph node removal in lung cancer surgery
This trial looks at complications from removing lymph nodes during surgery for non-small cell lung cancer. It may help doctors understand how to make surgery safer.
UlyanovskAges 18 years+ - NCT05104515RecruitingPhase 1
First cancer vaccine test for advanced lung, ovarian, or prostate cancer
This Phase 1 study tests OVM-200, a new cancer vaccine, to see how it is tolerated and how it affects the immune system in people with advanced NSCLC, ovarian cancer, or prostate cancer. You may be eligible if your cancer has already had approved treatment(s) and no further standard options are planned within the first two months.
London, LondonAges 18–75 - NCT04616209RecruitingPhase 1/Phase 2
Donor immune cell therapy for advanced lung cancer
This early-phase study tests immune cells given from a matched donor to treat advanced non-small-cell lung cancer. It aims to see how safe the treatment is and whether it can help control the cancer.
TaipeiAges 20–70
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for small cell lung cancer?
- Yes. Clin2 currently lists 1,490 recruiting small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Beyond the search
We also like to point to nonprofits doing real good in this area. We aren’t affiliated with them — we just admire the work.
- Stand Up To CancerPeople facing cancer across many types, through the research that leads to better treatments.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.